Suggested remit: To appraise the clinical and cost effectiveness of imlunestrant within its marketing authorisation for treating oestrogen receptor-positive, HER2-negative advanced breast cancer after endocrine treatment.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6373
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 December 2025 | Note - Note added to the project documents |
| 30 September 2025 | Invitation to participate |
| 25 October 2024 | Note - Note added to the project documents |
| 11 June 2024 | Note added to the project documents |
| 25 April 2024 - 24 May 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6373 |
| 25 April 2024 | In progress. Scoping commencing |
| 25 October 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 25 October 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual